Search Results

Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome.

Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS).

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591.

ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.

Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.

Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley

Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced that an 1 for 5 reverse split of its authorized share capital, was approved by the Company’s board of directors on May 29, 2023 and will become effective on June 21, 2024.

Piramal Pharma Limited, a leading global pharmaceuticals company, announced its standalone and consolidated results for the Fourth Quarter and Full Year ended 31st March 2024.

Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.

VolitionRx Limited, a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024.